Combo Product Dispute Resolution, Primary Mode Of Action Detailed By OCP
This article was originally published in The Gray Sheet
Executive Summary
Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns, according to a proposed rule published in the May 7 Federal Register
You may also be interested in...
Primary-Mode-Of-Action Rule For Combo Products Is Similar To Earlier Draft
FDA's "primary-mode-of-action" 1final rule for combination products largely mirrors the language of last year's proposed version, although the agency adds clarification on various issues raised by stakeholders
Primary-Mode-Of-Action Rule For Combo Products Is Similar To Earlier Draft
FDA's "primary-mode-of-action" 1final rule for combination products largely mirrors the language of last year's proposed version, although the agency adds clarification on various issues raised by stakeholders
Combo Product Coalition Drafting Proposal On Regulatory Selection Criteria
The Combination Product Coalition plans to submit a policy paper to FDA by the end of the summer proposing criteria for determining applicable regulations at various points in a combo product's lifecycle